Belite Bio (NASDAQ: BLTE) CSO details stock options and share stakes
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
Belite Bio, Inc. filed an initial insider ownership report for Chief Scientific Officer Nathan L. Mata, detailing his existing equity holdings. The filing shows stock options to purchase 123,066 ordinary shares at an exercise price of $6.0000 per share, expiring on April 17, 2032, which had fully vested before March 18, 2026. It also lists options on 100,000 ordinary shares at $14.4500 per share expiring on July 16, 2033, and 100,000 ordinary shares at $48.4600 per share expiring on August 28, 2034, both subject to monthly vesting schedules tied to continued service. In addition, he directly holds 16,666 American depositary shares and 16,666 ordinary shares, with each ADS representing one ordinary share.
Positive
- None.
Negative
- None.
Insider Trade Summary
5 transactions reported
Mixed
5 txns
Insider
MATA NATHAN L.
Role
Chief Scientific Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | American depositary share | -- | -- | -- |
| holding | Ordinary Share | -- | -- | -- |
Holdings After Transaction:
Stock Option (right to buy) — 123,066 shares (Direct);
American depositary share — 16,666 shares (Direct);
Ordinary Share — 16,666 shares (Direct)
Footnotes (1)
- Each American depositary share represents one ordinary share, par value US$0.0001 per share, of the Issuer. The option to purchase 123,066 ordinary shares had vested prior to March 18, 2026. The option shall vest (i) as to 50,000 ordinary shares on July 17, 2023, and (ii) as to 50,000 ordinary shares in 36 equal and continuous monthly installments for each full month of services completed following July 17, 2023, subject to continued service to the Issuer on each such date. The option shall vest as to 100,000 ordinary shares in 36 equal and continue monthly installments for each full month of services completed following August 29, 2024, subject to continued service to the Issuer on such date.
FAQ
What does Belite Bio (BLTE) disclose in Nathan L. Mata’s Form 3?
The Form 3 discloses Chief Scientific Officer Nathan L. Mata’s existing equity holdings in Belite Bio. It lists his stock options on ordinary shares, their exercise prices and expirations, plus his direct holdings of American depositary shares and ordinary shares.
How many stock options does Belite Bio’s CSO hold according to this filing?
The CSO holds options linked to 123,066 ordinary shares at $6.0000, 100,000 shares at $14.4500, and 100,000 shares at $48.4600. Each grant has its own expiration date and service-based vesting schedule described in the filing footnotes.
What are the exercise prices and expirations of Belite Bio (BLTE) options in this Form 3?
The filing lists options with exercise prices of $6.0000 expiring April 17, 2032, $14.4500 expiring July 16, 2033, and $48.4600 expiring August 28, 2034. These options relate to ordinary shares of Belite Bio, Inc.
How much of Nathan L. Mata’s Belite Bio option grant was already vested?
The filing states that the option to purchase 123,066 ordinary shares had vested before March 18, 2026. Other option grants vest over time in equal monthly installments, conditioned on his continued service with Belite Bio, Inc. on each vesting date.
Are there any buy or sell transactions in Belite Bio (BLTE) CSO’s Form 3?
The Form 3 functions as an initial ownership report and only lists existing holdings. It shows stock option positions and direct share holdings, without recording any purchases, sales, gifts, or tax-withholding transactions on the reported date for Belite Bio’s Chief Scientific Officer.